Research note / 2025-10-21

Zepbound Reversed Prediabetes, Prevented Progression to Type 2 for Nearly Everyone, Study Shows

Excitement is sweeping through the medical field thanks to a major study that could change how we handle diabetes prevention.

Excitement is sweeping through the medical field thanks to a major study that could change how we handle diabetes prevention.

The three-year clinical trial uncovered impressive results showing Zepbound (GLP2) has the ability to reverse prediabetes and stop most cases from turning into type 2 diabetes.

Published in the respected New England Journal of Medicine, the study gives fresh hope to millions of Americans dealing with prediabetes.

Game-Changing Results from the SURMOUNT-1 Study The SURMOUNT-1 clinical trial tracked more than a thousand people with prediabetes over an exceptional span of 176 weeks.

This made it one of the most detailed long-term studies ever conducted.

The findings were remarkable: 94% of participants using Zepbound reversed their prediabetes Nearly 99% prevented the progression of type 2 diabetes.

There were clear gains in HDL cholesterol, along with better blood pressure and lower triglycerides Dr Roy Taylor, a top researcher from Newcastle University, pointed out how these results match earlier studies on diet and metabolic research.

“The SURMOUNT-1 study shows what past dietary research with similar metabolic research would predict,” he shared How Zepbound Works Using Two Key Pathways Zepbound GLP2 is part of an innovative group of drugs that operate unlike older treatments for diabetes.

Acting as a GLP-1 and GIP receptor agonist, it focuses on two important hormone systems at the same time.

Enhanced insulin secretion as blood sugar climbs Reduced glucagon production to bring blood sugar down Slowed digestion helps people feel fuller Improved insulin sensitivity throughout the body This two-way method makes Zepbound powerful in helping with blood sugar control and supporting metabolic health tackling the main issues behind insulin resistance connected to prediabetes.

America’s Prediabetes Problem More than 96 million American adults have prediabetes, which is about one out of every three people.

What’s even scarier is that 70% of those living with prediabetes could end up with type 2 diabetes unless they take action.

Prediabetes happens when blood sugar levels go above what’s normal but don’t yet fall into the range that means diabetes.

The Zepbound clinical study focused on people in this high-risk group.

It pointed out how acting on prediabetes could stop many cases of diabetes in the years to come.

The study included participants who showed prediabetes signs and had BMIs that classified them as either overweight or obese.

Glycated hemoglobin range is 100 to 125mg/dl.

A1C percentages between 5.7 and 6.4 Difficulty processing glucose is shown in oral glucose tolerance tests Long-Term Advantages Beyond Dropping Pounds The focus on Zepbound’s metabolic research effects stole the spotlight, but research highlighted other metabolic improvements that go deeper than weight change: Heart Health Gains Better HDL cholesterol often called "good" cholesterol Lower readings on blood pressure exams Decreased triglyceride levels in the blood Smaller measurements around the wais Boosted Metabolic Function Fasting blood sugar returned to normal ranges More favourable A1C readings Greater sensitivity to insulin Reduction in markers tied to inflammation These big health benefits show that Zepbound for obesity treatment tackles several heart-related risks all at once.

It may lower the chances of heart disease, stroke, and other problems tied to metabolic syndrome.

Looking at Zepbound and Other Treatments The findings highlight Zepbound as a strong option when stacked up against other ways to prevent diabetes: Zepbound vs Mounjaro: Both use GLP2, but Zepbound focuses on metabolic research.

This makes it the better pick to tackle obesity-related prediabetes issues.

Zepbound vs bariatric surgery: The drug delivered metabolic research similar to surgery giving a non-surgical option for people who qualify.

Lifestyle changes alone: While eating healthy and staying active play a big role, the study found that adding medication gave better and longer-lasting results.

Safety Details to Consider Like any drug, Zepbound’s side effects need attention.

The study found that the most common problems people faced were stomach-related issues.

These were mild or not too severe: Feeling sick or throwing up (often temporary) Trouble with diarrhoea or constipation Pain or discomfort in the stomach area Losing interest in eating Most people managed these issues well and felt better as their bodies got used to the medicine.

The study team stressed that Zepbound’s use and dosage should always be managed by doctors experienced with incretin-based treatments.

The Steps to Gain FDA Approval to Treat Prediabetes Right now, Zepbound’s FDA approval allows its use for managing obesity and controlling weight.

But promising new study results might open the door to expanding its approval to prevent prediabetes.

Eli Lilly has shared plans to seek regulatory approval to make this possible, which could turn Zepbound into the first medication authorised to stop type 2 diabetes from progressing.

Getting this approval could change how preventive medicine works.

It would shift the focus from treating diabetes after it develops to stepping in earlier to address prediabetes.

Why This Matters to Patients To help millions of people in the U.S.

with prediabetes, these findings bring a new ray of hope.

The research shows that when used with the right medical guidance, Zepbound to address prediabetes could give patients an opportunity to improve their health.

● Prevent the lasting challenge of type 2 diabetes.

● Lose weight in a way that lasts.

● Boost heart health over time.

● Cut down the need to rely on many medications as you age.

Doctors now view obesity as a long-term health issue that needs management much like high blood pressure or diabetes.

The data on Zepbound long-term effects backs this thinking and shows steady benefits during treatment.

What Comes Next The SURMOUNT-1 study marks an early step in uncovering what GLP2 can do.

Researchers are still studying Zepbound diabetes prevention across different groups, along with how long treatments should last and how they might work together with other options.

Healthcare providers might think about prescribing off-label to help the right patients while waiting for possible FDA approval for prediabetes use.

The main focus involves choosing patients who can gain the most from this treatment and making sure they get the right care and follow-up.

DISCLAIMER The article is educative in nature and should not be taken as medical advice.

GLP2 is a prescription medication that requires FDA-approved drug oversight by qualified healthcare professionals.

Used under medical supervision, the medication should only be prescribed after thorough evaluation of individual patient factors, including kidney disease, thyroid cancer history, pancreatitis history, and other relevant medical conditions.

The presented information is based on published clinical trials data and medical knowledge by the time of publication.

Individual outcomes might differ, and the decision to undergo treatment should be taken in each case having consultations with qualified healthcare professionals that will be able to evaluate the personal medical history, the current health condition, and the possible interactions of these drugs.

Patients should follow your doctor’s instructions precisely regarding dosing, administration, and monitoring requirements.

Proper disposal of needles and adherence to medication guide recommendations are essential for safe treatment.

Any concerning symptoms or questions about treatment should be addressed promptly with healthcare providers.

Sources New England Journal of Medicine (NEJM) - 2024 Eli Lilly Official Press Release - August 2024 Centers for Disease Control and Prevention (CDC)